Activation of ERK, and p38 MAPK signaling molecules modulates T cell function, exerting differential effects on T cell development, cell cycle progression, and apoptosis (8, 14, 26) . ERK signaling is critical for positive selection, promotes cell cycle progression, and inhibits apoptosis (13, 19, 20) , while p38 signaling is necessary for negative selection, promotes cell cycle arrest, and induces apoptosis (1, 12) . Alterations in ERK signaling have been associated with chronic inflammatory autoimmune conditions such as lupus and rheumatoid arthritis (15, 25) and with pathogenic viral infections (30) . Several viral proteins are known to interact with MAPK signaling pathways (29) . Attenuated ERK1/2 phosphorylation responses to T cell receptor stimulation have been observed in unfractionated peripheral blood mononuclear cells (PBMCs) in HIV-1 infection (18) .
HIV-1 disease is characterized by immune inflammation, with highly elevated CD8 ϩ T cell-activation levels and lower levels of CD4 ϩ T cell-activation, measured by joint surface expression of CD38 and HLA-DR markers. A set point CD8 ϩ T cell-activation level is established in early untreated HIV-1 infection and predicts clinical outcome independently of plasma HIV-1 RNA levels (9) . However, the functional significance of CD38 and HLA-DR coexpression on CD8 ϩ T cells, a population that is not infected by HIV-1, has not been resolved. A detailed understanding of the functional changes to activated CD8 ϩ T cells may aid in the development of therapeutic strategies to halt or reverse HIV immunopathogenesis.
HIV-1-associated CD8 ϩ T cell activation has been linked to atypical T cell differentiation, (5) a process that involves MAPK signaling pathways (11) . Previous studies of HIV-1-infected adults have reported altered CD8 ϩ T cell differentiation profiles, specifically, a large expansion of transitional intermediate/late memory (CD45RA Ϫ CD28 Ϫ CD27 ϩ/Ϫ ) subsets and a reduction in the proportion of naïve (CD27 ϩ CD28 ϩ CD45RA ϩ ) subsets (2, 3, 22) . An expansion of intermediate memory cells during HIV-1 infection may have negative functional consequences, such as increased CD8 ϩ T cell replicative senescence or a failure to differentiate into functional effectors (28) . In contrast, CD8 ϩ T cells in the "terminally differentiated" CD45RA ϩ CD27 Ϫ pool, referred to as the effector/ memory RA (EMRA) pool, exhibit enhanced effector activities (27) . An expanded T EMRA CD8
ϩ T cell population has been associated with a lower viral load set point in early HIV-1 infection (21) .
To evaluate MAPK signaling in activated CD8 ϩ T cells during early untreated HIV-1 infection, we implemented a flow cytometry-based signaling assay termed "phosflow" (7, 24) . Phosflow combines multiparameter phenotyping of surface antigen expression with simultaneous detection of phosphorylated forms of intracellular signaling protein intermediates. We examined ERK (ERK1/2) and p38 phosphorylation responses to phorbol 12-myristate 13-acetate and ionomycin (PMAϩI) stimulation at the single-cell level in T cell subsets defined by expression of CD38, HLA-DR, and Tim-3. PMA is an analog of diacylglycerol, a key mediator of MAPK signaling through protein kinase C (PKC) (4) . Ionomycin stimulates Ca 2ϩ release from the endoplasmic reticulum, activating Ca 2ϩ -sensitive enzymes and synergizing with PMA (6). PMAϩI is a potent stimulator of MAPK signaling cascades, resulting in the accumulation of phosphorylated, kinase-active ERK1/2 and p38 signaling intermediates (10) . We hypothesized that activated CD38
ϩ HLA-DR ϩ CD8 ϩ T cells would display intact but attenuated MAPK signaling responses in HIV-1-infected adults compared to HIV-1-negative controls. Our findings did not confirm our hypothesis but instead revealed a novel, large population of highly activated CD8 ϩ T cells not merely lacking robust MAPK pathway signaling responses but also displaying a complete abrogation of signaling through the ERK1/2 MAPK module.
MATERIALS AND METHODS
Study subjects. Cryopreserved PBMCs were selected from the OPTIONS cohort study of early HIV-1 infection in San Francisco. The first clinical visit was always prior to administration of antiretroviral treatment. Early HIV-1 infection was identified as previously described (17) . HIV-1-negative risk-matched controls were identified through OPTIONS project screening of adults with suspected HIV-1 sexual exposure who subsequently were found to be HIV-1 negative. All persons gave informed consent to participate, and the UCSF Committee on Human Research approved this study.
Cell culture, staining, stimulation, and flow-cytometric analysis. Cryopreserved PBMCs stored by the UCSF/AIDS Research Institute (ARI) AIDS Specimen Bank were thawed, and 1 ϫ 10 6 cells were immediately stained for T cell immunophenotypic markers. The remaining cells were allowed to rest for 18 h in 5% cRPMI (RPMI 1640 medium; UCSF Cell Culture Facility [CCF]) supplemented with 5% fetal bovine serum (FBS) (JR Scientific), 1% penicillin-streptomycin (CCF), 10 mM HEPES (CCF), 2 mM L-glutamine (Invitrogen), and 10 g/ml DNase I (Sigma). Cells (1 ϫ 10 6 ) were stained with aqua amine reactive dye (AARD; Invitrogen) and then anti-CD3 Alexa 700 (clone SP34-2), anti-CD4 PE-TR (clone S3.5), and anti-CD8 Pacific Blue (clone 3B5), along with anti-CD38 PE-Cy5 (clone HIT2), anti-HLA-DR APC-H7 (clone L243), and antiTim-3 PE (clone 344823) to identify activated and exhausted T cell subsets, respectively, or anti-CD28 PE-Cy5 (clone CD28.2), CD27 APC-eF780 (clone O323), and CD45RA PE (clone HI100) to identify differentiation subsets. Cells were stimulated with 100 ng/ml PMA and 1 g/ml ionomycin (both from Sigma) for 15 min at 37°C, fixed in 4% paraformaldehyde (PFA; Electron Microscopy Sciences), permeabilized with custom phosflow buffer 643435 (courtesy of BD Bioscience), stained for intracellular phosphorylation-specific ERK1/2 Alexa 488 and p38 Alexa 647 (p-ERK1/2 and p-p38, clones 20A and 36/p38, respectively), suspended in 1% PFA in PBS, and analyzed by flow cytometry using a 4-laser LSR-II instrument (BD Bioscience). AARD, CD4, and CD8 were obtained from Invitrogen, CD3, CD38, HLA-DR, CD28, CD45RA, p-ERK1/2, and p-p38 from Becton Dickinson, CD27 from eBiosciences, and Tim-3 from R&D Systems. Fluorescence minus one (FMO) samples were prepared for each fluorochrome to facilitate gating. Anti-mouse or anti-rat IgG-coated beads (Becton Dickinson) were stained with each fluorochrome-conjugated antibody separately and used for software-based compensation. Data analysis was performed using FlowJo (Treestar).
Five CD8 ϩ T cell maturation stages were defined by the use of three markers:
(gating is depicted in Fig. S3 in the supplemental material). Statistical analysis. Statistical analysis was performed using GraphPad Prism statistical software (GraphPad Software, San Diego, CA). The nonparametric Mann-Whitney U was used for comparison tests, and the Spearman Rank test was used for correlation analyses. Measures of central tendency are expressed as medians and interquartile ranges (IQRs; given in the form 25th percentile, 75th percentile).
RESULTS

Clinical cohort description.
Frozen peripheral blood mononuclear cells (PBMCs) were obtained from the OPTIONS Project cohort study of early HIV-1 infection (San Francisco General Hospital, University of California, San Francisco). The study included 79 recently HIV-1-infected adults and 21 HIV-1-negative adult risk-matched controls (Table 1) . PBMC samples were obtained during early infection prior to initiation of an antiretroviral treatment (HIV-1-infected patients) or during screening for HIV-1 infection that subsequently proved negative (controls). HIV-1-infected adults had lower CD4 ϩ counts and higher CD8 ϩ T cell activation than controls and had been infected an estimated median 98 days at the time of the study (Table 1) .
A subset of CD8 ؉ T cells refractory to ERK1/2 phosphorylation is expanded in early untreated HIV-1 infection. To examine MAPK pathway intracellular signaling events in T cell subsets, phosflow analysis was performed on PBMCs to detect phosphorylation of ERK1 and -2 (p-ERK1/2) and p38 (p-p38). Figure 1 illustrates a typical example of the CD8 ϩ T cell p-ERK1/2 and p-p38 response to PMAϩI stimulation and shows an increase in median fluorescence intensity (MFI) of p-ERK1/2 and p-p38 expression relative to unstimulated controls. Strikingly, in HIV-1-infected subjects, a large population of CD8 ϩ T cells do not respond to PMAϩI stimulation and have a p-ERK1/2 MFI similar to that of the unstimulated control (Fig. 1A, panel i) . The resulting bimodal p-ERK1/2 histogram profile was gated into two distinct CD8 ϩ subsets based on p-ERK1/2 responsiveness. The histogram peak containing cells shifted positively along the p-ERK1/2 axis was labeled p-ERK ϩ , and this subset is referred to as p-ERK1/2 responsive. The histogram peak containing cells that failed to shift along the p-ERK1/2 axis was labeled p-ERK Ϫ , and this subset is referred to as p-ERK1/2 refractory. The term "refractory" was chosen to reflect the fact that while this CD8 ϩ T cell subset exhibits an impaired p-ERK1/2 response after 15 min of PMAϩI stimulation, the cells might still retain the capacity to respond through ERK1/2 with different signaling kinetics.
As illustrated in Fig. 1A and in Table S1 in the supplemental material, the frequency of CD8 ϩ p-ERK1/2-refractory T cells was significantly expanded in HIV-1-infected individuals relative to uninfected controls (median frequencies [IQRs], 19.0 [12.1, 28.7] for the infected group and 7.1 [3.4, 10.4] for the uninfected group; P Ͻ 0.0001). The fraction of CD4 ϩ T cells (Fig. 1B and data not shown) , although the effect was more modest than for CD8 ϩ T cells. The frequency of CD8 ϩ p-ERK1/2-refractory T cells exhibited a significant correlation with viral load (Spearman r ϭ 0.39, P ϭ 0.0007) but not with CD4 ϩ T cell count (Spearman r ϭ Ϫ0.02, P ϭ 0.8). To examine the relationship between activation and the p-ERK1/2-refractory population, CD8
ϩ T cells were divided into subsets with the activation markers CD38 and HLA-DR. We found that p-ERK1/2-refractory cells were primarily contained within the highly activated CD38 ϩ HLA-DR ϩ population (Fig.  1A, panel iv) . In HIV-1-infected patients, the frequency of CD8 ϩ p-ERK1/2-refractory cells strongly correlated with CD38 ϩ HLA-DR ϩ frequency (Spearman r ϭ 0.71, P Ͻ 0.0001).
To define the p-ERK1/2-refractory phenotype, CD8 ϩ T cells were gated for the presence or absence of CD38, HLA-DR, and Tim-3 markers individually, and histogram profiles of p-ERK1/2 MFI in the single-marker subsets were examined (Fig. 2) To explore the p-ERK1/2-refractory phenotype, individually gated CD38, HLA-DR, and Tim-3 subsets (Fig. 2) were used to generate eight Boolean gate populations in both HIV-1-infected and uninfected populations (Fig. 3) . As expected, we observed significant expansions of activated (CD38 ϩ HLA-DR ϩ Tim-3 ϩ/Ϫ ) subsets, and a reduction in the nonactivated (CD38 Ϫ HLA-DR Ϫ Tim-3 Ϫ ) subset, in recently HIV-1-infected patients versus controls (Fig. 3A) . The frequency of p-ERK1/2-refractory cells was significantly increased in 7 of 8 Boolean subsets in HIV-1-infected patients versus uninfected controls (Fig. 3B) . Notably, the highly activated CD38
ϩ HLA-DR ϩ Tim-3 Ϫ subset contained the largest proportion of p-ERK1/2-refractory cells in both HIV-1-infected and control subjects (medians [IQRs], 47.6% [32. 1, 66.8] for the infected group and 15.4% [9.7, 36.7] for the uninfected group) (Fig. 3B,  columns 3 and 4) , and the level was significantly higher in HIV-1-positive patients (P Ͼ 0.0001).
Next, we examined the magnitude of the PMAϩI-induced p-ERK1/2 response in CD38, HLA-DR, and Tim-3 Boolean gated subsets, recorded as fold change (FC) in p-ERK1/2 MFI upon stimulation. The p-ERK1/2 FC response tended to be lower for the HIV-1-infected group than for uninfected controls in all subsets. Significant differences between infected and uninfected groups were observed in highly activated CD38 ϩ HLA-DR ϩ Tim-3 ϩ/Ϫ and CD38 ϩ HLA-DR Ϫ Tim-3 Ϫ populations (Fig. 4A) . There was no significant difference in p-ERK1/2 FC between groups in any of the CD8 ϩ T cell populations that did not express CD38. In HIV-1-infected patients, the activated CD38 ϩ HLA-DR ϩ Tim-3 Ϫ subset exhibited the lowest p-ERK1/2 response (FC ϭ 2.47 [IQR, 1.28, 3.93]). The reduced magnitude of p-ERK1/2 FC response in highly activated subsets was not attributable to differences in unstimulated (basal) p-ERK1/2 levels, as there were no significant differences in p-ERK1/2 MFIs between CD38 ϩ HLA-DR ϩ double-positive subsets and subsets not expressing HLA-DR (Fig. 4B , compare column 1 with column 5 and column 3 with column 7). Taken together with the finding that almost 50% of CD8 ϩ T cells in the CD38 ϩ HLA-DR ϩ Tim-3 Ϫ compartment were p-ERK1/2 refractory (Fig. 3B) , these results indicate that the reduced p-ERK1/2 responsiveness (p-ERK1/2 FC) observed in the highly activated CD38 ϩ HLA-DR ϩ Tim-3 Ϫ subset in HIV-1-infected individuals is primarily due to the large percentage of p-ERK1/2-refractory cells present in this compartment, not simply an attenuated but intact per-cell responsiveness.
Similar to the p-ERK1/2 response, the PMAϩI-induced p38 phosphorylation response (fold change in p-p38 MFI) was significantly reduced in highly activated CD38 ϩ HLA-DR ϩ subsets compared to populations not coexpressing these two markers (left four columns of Fig. S2A in the supplemental  material) . However, unlike with p-ERK1/2, significantly higher unstimulated basal p-p38 levels were observed in CD38 ϩ HLA Ϫ DR ϩ subsets (Fig. S2B) . These data indicate that, in contrast to p-ERK1/2, reduced p-p38 fold changes in activated CD8 ϩ T cell compartments during early untreated HIV-1 infection are at least partially driven by higher basal levels of p38 phosphorylation.
Impairment of p-ERK1/2 responses, which participate in cell cycle and cell differentiation processes in CD8 ϩ T cells (13), might associate with the shifts in T cell maturation profiles observed in HIV-1 infection. We therefore examined the coexpression of CD45RA, CD28, and CD27 in PMAϩI-stimulated samples stained for p-ERK1/2 expression. Five maturation stages were defined and are described in Materials and Methods. As previously described, recently HIV-1-infected, treatment-naïve patients exhibited significantly elevated frequencies of intermediate (CD45RA Ϫ CD28 Ϫ CD27 ϩ ) and late (CD45RA Ϫ CD28 Ϫ CD27 Ϫ ) memory maturation stages relative to HIV-1-negative controls ( Fig. 5A ; see also Table S1 in the supplemental material).
Figure 5B illustrates the proportion of p-ERK1/2-refractory cells that were identified within each of the five maturation stages (see Materials and Methods for descriptions of the stages). We observed p-ERK1/2-refractory cells in all stages in both HIV-1-infected and uninfected subjects, but they differed substantially in distribution by HIV infection status and differentiation state. The frequency of p-ERK1/2-refractory cells was lowest in the naïve (CD45RA ϩ CD28 ϩ CD27 ϩ ) compartment and increased in proportion through to the late memory stage (CD45RA Ϫ CD28 Ϫ CD27 Ϫ ) in both HIV-1-infected and HIV-1-negative individuals (Fig. 5B) . With the exception of naïve-phenotype CD8 ϩ T cells, the p-ERK1/2-refractory population was significantly expanded or trended toward significant expansion in every maturation stage in recently HIV-1-infected, treatment-naïve adults relative to HIV-1-negative adults. These expansions of the p-ERK1/2-refractory population were most pronounced in the intermediate (CD45RA
Ϫ
CD28
Ϫ CD27 ϩ ) and late (CD45RA Ϫ CD28 Ϫ CD27 Ϫ ) memory populations. These are the same two memory differentiation stages that are themselves expanded in frequency in HIV-1 infection (2, 3, 22) . 
DISCUSSION
We observed a highly expanded p-ERK1/2-refractory CD8 ϩ T cell population residing within the activated (CD38 ϩ HLA-DR ϩ ) CD8 ϩ T cell compartment in HIV-1-infected adults. In contrast, we did not observe a large expansion of a p-ERK1/ 2-refractory population in CD4 ϩ T cells in HIV-1 infection. In HIV-1-negative risk-matched controls, we observed a smaller, lower-frequency population of p-ERK1/2-refractory CD8 ϩ T cells, suggesting that a functional blockade in the ERK1/2 MAPK pathway is a normal, if far less common, process in CD8 ϩ T cells in healthy adults. CD8 ϩ T cells refractory to phosphorylation of ERK1/2 not only were highly activated but also were enriched in intermediate (CD45RA
T cell populations, which are greatly expanded in HIV-1-infected persons (3, 22) . However, we found the ERK1/2-refractory phenotype to be present in both CD28 ϩ and CD28 Ϫ CD8 ϩ T cells, suggesting that the loss of PMAϩI-induced ERK1/2 responsiveness was not due exclusively to the loss of CD28 expression, which signals through ERK1/2.
In contrast, CD8 ϩ T cells bearing the immunomodulatory receptor Tim-3 did not display this refractory signaling phenotype, suggesting that a proportion of Tim-3-bearing cells retain the ability to respond to certain stimuli during HIV-1 infection (16) and may be readily converted to effectors through blockade of Tim-3 ligands. Tim-3, commonly referred to as an exhaustion marker, may mark a population of CD8 ϩ T cells that, while strongly repressed in exhibiting effector activities, retain functional signaling pathways and perhaps full effector activities, given the appropriate stimuli. Additionally, we observed the appear-ance of a bilobed CD8 ϩ population among HIV-1-infected individuals not apparent in HIV-1-negative risk-matched controls ( Fig. 2; also Fig. S1 in the supplemental material and data not shown) (23) . We observed that the majority of activated (CD38
ϩ "low" cells exhibited the p-ERK1/2-refractory phenotype (data not shown).
In this study, we found evidence for and against the previously reported higher basal MAPK pathway phosphorylation in HIV-1-infected persons (24) . Specifically, we found that p38 basal phosphorylation levels were higher in activated (CD38 ϩ HLA-DR ϩ ) CD8 ϩ T cell subsets, which likely contributed to the lower fold changes in p-p38 MFI observed in activated compartments (see Fig. S2 in the supplemental material) . In contrast, reduced fold changes in p-ERK1/2 MFI observed in activated CD8
ϩ T cells was not due to higher basal phosphorylation levels (Fig. 4B) but instead was driven primarily by the presence of cells refractory to potent PMAϩI stimuli (Fig. 3B) . These data suggest that HIV-1 infection, and associated activation levels, may differentially impact ERK1/2 and p38 MAPK modules.
An abrogated ERK1/2 signaling response indicates the presence of a block in the MAPK pathway. PMA induces ERK1/2 phosphorylation through activation of PKC, which in turn positively modulates activity of the Raf scaffolding protein upstream of ERK1/2 (4). This suggests a functional impediment either at the level of PKC or in one of the downstream components in the pathway, such as Raf, MEK, or ERK1/2 itself. Alternatively, low ERK1/2 expression levels or the induction of phosphatases with specificity for ERK1/2 might confer the observed phenotype. Abrogation of ERK1/2 signaling in a large fraction of CD8 ϩ T cells could have multiple deleterious functional consequences. These include reduced T cell prolif- 
